文献速递肺栓塞与肺血管病

肺动脉高压的表型研究进展

Phenotypes in pulmonary hypertension.
PubMed 文献 · Eur Respir J · 2024-09-05

本文综述了肺动脉高压临床分类的演变及表型研究进展,指出影像学、计算科学和多组学方法揭示了现有分类内新的表型和亚表型;在动脉性肺动脉高压中识别出独特分子谱表型可能导向精准治疗,而第2、3、4、5组中也涌现出与预后和治疗相关的新表型。

要点

  • 多组学与影像学进展推动肺动脉高压新表型识别
  • 动脉性肺动脉高压中独特分子谱表型可能导向精准治疗
  • 第2、3组中新表型反映持续严重肺血管病变且预后更差

核心结论

  • 肺动脉高压临床分类随机制、病理生物学和治疗反应认识而演变,新表型将影响预后工具和临床试验设计。

研究设计与样本

  • 综述性文章,检索范围未在摘要中报告。

主要发现

  • 影像学、计算科学和多组学方法揭示了现有临床分类内的潜在表型和亚表型。
  • 在动脉性肺动脉高压中识别出具有独特分子谱的新表型,可能导向新的精准治疗。
  • 部分动脉性肺动脉高压患者表型更接近左心疾病(第2组)和肺疾病(第3组),具有预后和治疗意义。
  • 第2组和第3组中出现反映持续严重肺血管病变的新表型,预后更差但不同于动脉性肺动脉高压。
  • 第4组(慢性血栓栓塞性肺疾病)和结节病(第5组)的表型分析整合临床、血流动力学和影像特征指导治疗,但多组学方法应用稀少。

临床怎么用

  • 临床可关注肺动脉高压表型异质性,利用影像和多组学信息辅助预后判断和治疗选择。

局限性

  • 摘要未报告综述的检索范围、纳入标准及证据等级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical classification of pulmonary hypertension (PH) has guided diagnosis and treatment of patients with PH for several decades. Discoveries relating to underlying mechanisms, pathobiology and responses to treatments for PH have informed the evolution in this clinical classification to describe the heterogeneity in PH phenotypes. In more recent years, advances in imaging, computational science and multi-omic approaches have yielded new insights into potential phenotypes and sub-phenotypes within the existing clinical classification. Identification of novel phenotypes in pulmonary arterial hypertension (PAH) with unique molecular profiles, for example, could lead to new precision therapies. Recent phenotyping studies have also identified groups of patients with PAH that more closely resemble patients with left heart disease (group 2 PH) and lung disease (group 3 PH), which has important prognostic and therapeutic implications. Within group 2 and group 3 PH, novel phenotypes have emerged that reflect a persistent and severe pulmonary vasculopathy that is associated with worse prognosis but still distinct from PAH. In group 4 PH (chronic thromboembolic pulmonary disease) and sarcoidosis (group 5 PH), the current approach to patient phenotyping integrates clinical, haemodynamic and imaging characteristics to guide treatment but applications of multi-omic approaches to sub-phenotyping in these areas are sparse. The next iterations of the PH clinical classification are likely to reflect several emerging PH phenotypes and improve the next generation of prognostication tools and clinical trial design, and improve treatment selection in clinical practice.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Weatherald J, Hemnes AR, Maron BA, et al. Phenotypes in pulmonary hypertension. Eur Respir J. 2024. PMID: 38964779. doi:10.1183/13993003.01633-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。